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The organizers of the Camerino Receptor Symposia survey the development of receptorology. They trace the
course from the first Symposium in 1978, which laid the foundation for Pirenzepine, the first selective muscarinic
antagonist, to the 2010 Symposium, which highlighted the utility of functional simple domain antibodies
(nanobodies) as novel G Protein-Coupled Receptor (GPCR) modulators. This 30-year period sees the acceptance of
terms such as G-protein, auto- and heteroreceptors, site-directed mutagenesis, chimeric receptors, constitutive
activity, inverse agonism, and orphan receptors. GPCRs are finally a reality and Langley and Ehrlich, if they returned
to their laboratories, would be proud of how their intuitions have been realized.
Keywords: G Protein-Coupled Receptor (GPCR); Camerino symposium; Receptorology; Mutagenesis; Chimeric
receptor; Orphan receptorReview
“G protein-coupled receptors are integral membrane
glycoproteins, containing a seven-transmembrane helical
protein-fold, that mediate a variety of signaling pro-
cesses, such as neurotransmission, hormonal response,
olfaction, and light transduction.” It’s been a long
journey to arrive at this definition. To us, the path really
began on Monday September 11, 1978, at Camerino,
when the old room of the Chemistry Institute filled with
researchers interested in studying receptor chemistry
that was still a very young subject. Despite the publica-
tion of several physiological and biochemical works, the
physical existence of receptors remained controversial.
This skepticism was expressed by Raymond Ahlquist, a
respected pharmacologist. Even though he had differen-
tiated the adrenoreceptors as α and β in 1945, Ahlquist
still wrote in 1973 “This would be true if I were so
presumptuous as to believe that α and β receptors really
did exist. There are those that think so and even propose
to describe their intimate structure. To me they are an
abstract concept conceived to explain observed responses* Correspondence: mario.giannella@unicam.it
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reproduction in any medium, provided the origof tissues produced by chemicals of various structure”
(Ahlquist 1973).
Sitting in the front row at the Chemistry Institute that
day were Bernard Belleau, Philip S. Portoghese, Peter G.
Waser, and Pietro Pratesi, the leader of one of the few
Italian teams devoted to studying receptors, particularly
the correlation between the chemical-physical properties
of sympathomimetic amines and their biological activity
(Pratesi 1958). These four researchers had been invited
to Camerino as Speakers at the International Symposium
on ‘Recent Advances in Receptor Chemistry’ by our
research team, whose reputation was based on just one
paper published (after careful revision!) in the Journal of
Medicinal Chemistry (Gualtieri et al. 1974).
During the four-day meeting, receptor theory, neuro-
transmitter membrane receptors, quantitative structure-
activity relationships, and computer procedures for
rationalizing drug-receptor interactions were the subjects
of lively discussion and debate, particularly energized by
E. J. Ariëns who, in 1965, had established the prestigious
monograph series Molecular Pharmacology, published by
Academic Press (Ariens 1965). In his opening lecture,
Ariëns hypothesized the existence of sites of action and
sites of binding and therewith the existence of silent
receptors in membrane proteins with receptor functions.. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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of them binding to their own specific receptor sites (two-
state model), were thought to be linked by an allosteric
interaction. The exceptional scientific atmosphere of the
meeting fostered the beginning of a collaboration between
Nigel Birdsall, one of the young English talents more
involved in receptor study, and Rudolf Hammer, an
authoritative researcher at the German pharmaceutical
company Boehringer Ingelheim. Birdsall and Hammer
eventually worked together to produce an extensive study
of Pirenzepine, the first selective muscarinic antagonist,
which led to our knowledge of muscarinic receptor
heterogeneity. Nevertheless, the content of receptorology
then was still so vague that Belleau, in the Preface of the
Proceedings published at the end of the meeting, stated
“The hypothetical borders delineating the field of receptor-
ology are so vague and fuzzy that it is hardly possible to
provide a clear definition of that science” (Gualtieri et al.
1979). As an example, transduction mechanisms antici-
pated that a receptor, interacting with its hormone, could
link and activate the enzyme adenylyl cyclase (mobile
receptor hypothesis) so forming the second messenger
cAMP (Cuatrecasas et al. 1975).
The discovery of a protein acting as transducer
between membrane receptor and adenylyl cyclase signifi-
cantly increased our knowledge of the molecular events
that convey signaling from the outside to the inside of
the cell. Alfred Gilman, after purifying this protein,
called it Gs-protein (Gilman 1987). At the beginning of
the 1980s, a number of observations lead to the intro-
duction of the ‘ternary complex model’ to describe the
receptor interaction between G-proteins and endo-
genous ligands (De Lean et al. 1980) and the quantita-
tion of high (G-protein coupled) and low (not coupled)
affinity states of the receptor (Kent et al. 1980). Several
novel technologies were developed, including radioligand
binding and affinity labeling techniques, detergent
solubilization, affinity chromatography purification, and
lipid reconstitution. These enabled the fruitful and effect-
ive isolation and characterization of receptor processes.
For example, the new binding affinity techniques were
applied to new large natural and synthetic compounds.
This led to the discovery of receptor subtypes in what was
previously thought to be a homogeneous system.
Interdisciplinary collaboration between medicinal chem-
ists, pharmacologists, biochemists, and molecular biolo-
gists was essential to achieving these advances. This was
recognized by the first Camerino Symposium and by every
subsequent edition. Such interdisciplinary collaboration
led to the isolation and purification of the β2-adrenore-
ceptor and its characterization as a glycosylated and
phosphorylated polypeptide chain of MW ~ 60–65000 Da
(Benovic et al. 1984). The next step was the reconstitution
in phospholipid vesicles of this protein and the verificationof its functionality maintenance (Cerione et al. 1983).
These advances were reflected in the 1983 meeting, ‘High-
lights in Receptor Chemistry’, whose main topics included
Langer’s work in describing presynaptic receptors in 1978
(Langer 1978) (subdivided at Camerino for the first time
into auto- and hetero-receptors), the description of the
dopaminergic receptor’s topography with the ‘receptor
mapping’ technique, and a first application of computa-
tional procedures in classifying drug and receptor conge-
ners. In the opening article of the Proceedings, David
Triggle wrote “From cloudy and uncertain beginnings we
now with confidence can discuss receptor structures, coup-
ling, diseases, defects and can use this knowledge to design
new pharmacologic and therapeutic tools” (Melchiorre
and Giannella 1984).
The advent of recombinant DNA technology in the
1980s provided new knowledge of the amino acid
sequence of receptors. At the same time, their molecular
mechanism of activation was explored using site-
directed mutagenesis, chemical synthesis, and molecular
modeling in a combined approach. Together with com-
puter graphics, valuable information was obtained
concerning a receptor’s three-dimensional structure and
the specific amino acids involved in a given interaction.
The β2-adrenoreceptor was the first to be cloned and its
architecture acknowledged as a homologue of the visual
pigmet rhodopsine (Dixon et al. 1986), whose entire
amino acid sequence had been determined in 1982
(Ovchinnikov 1982). Hypotheses on the functioning
mechanism of the receptor revealed a linkage between
the receptor sequence and G-protein transduction. For
this reason, researchers began to think that most GPCRs
might share a similar arrangement (Dohlman et al.
1987). Robert Lefkowitz, who won the Nobel Prize in
Chemistry with Brian Kobilka in 2012 for their pioneer-
ing work in studying seven transmembrane receptors
(7TMRs, ironically called “The magnificent seven” by
Lefkovitz) wrote “I never imagined that the superfamily
of 7TM receptors would grow so large and diverse”
(Lefkowitz 2004). Indeed, ions, organic odorants, amines,
peptides, proteins, lipids, nucleotides, and even photons
were identified as possible agents able to mediate their
message through the 7TMRs. In 1987, it was even
discovered that some gases could perform a similar role,
with nitric oxide (NO) being the first such finding (Palmer
et al. 1987). John Vane, Nobel Prize winner in Physiology
and Medicine in 1982, took part in the 1987 Camerino
Symposium. In his opening lecture ‘Adventures in
Bioassay’, he wrote of the “pharmacology and physiology
surprise… that one of the most fascinating mediators is a
simple one-to-one combination of the main elements of the
atmosphere” (Melchiorre and Giannella 1988).
At the end of the 1980s, Fulvio Gualtieri’s lecture on 1,3-
oxathiolane isosteric analogs of muscarinic 1,3-dioxolane
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the synthesis of Lamivudine, a powerful inhibitor of reverse
transcriptase (introduced in the following symposium). In
this molecule, the 1,3-oxathiolane scaffold, bound to a pyr-
imidine ring, simulates the ribose nucleus (Soudeyns et al.
1991). This edition of the Symposium saw the beginning of
an Italo-Dutch collaboration through a scientific twinning
between the Camerino group and a group at Vrije
Universiteit (Amsterdam) led by Prof. Henk Timmerman.
In the 2007 edition, ‘An Overview of Receptor Chemistry’,
this collaboration was extended to the Cyprus Conference
held in Limassol and directed by Prof. Alexandros
Makriyannis, director of the Center for Drug Discovery at
Northeastern University (Boston). SAR studies yielded
more and more selective compounds, allowing the
differentiation of many receptor subtypes. As per Fisher’s
metaphor (Fischer 1894), these were the keys that
unlocked the labyrinth. At the same time, the mechanisms
preceding and following ligand-receptor interaction were
also studied.
The first mutagenesis studies involved the design of
structures resulting from the combination of the se-
quences of multiple receptors (chimeric receptors)
(Ostrowski et al. 1992; Strader et al. 1994) or structures
with one or more mutated amino acids in specific
regions of the receptor polypeptide (site-directed muta-
genesis). One of the first chimeras was created by stitch-
ing together different sections of α2a- and β2-adrenergic
receptors (Kobilka et al. 1988). It showed that residues
in the membrane span produce the ligand-binding speci-
ficity, whereas the sequences in the amino and carboxyl
terminal portion of the third intracellular loop produce
the specificity binding to Gs or Gi. Equally important
are the results that Susanna Cotecchia obtained by
modifying four amino acids of the third cytoplasmic
loop of the α1B-adrenergic receptor (Cotecchia et al.
1992). She presented these results at the 1999 sympo-
sium (Cotecchia et al. 2000). These approaches eluci-
dated the role of specific regions of the sequence of the
polypeptide chain or of single amino acids, some of
which gave rise to constitutively activated receptors. The
probable elimination of intermolecular interactions,
which are essential in keeping the receptor in an inactive
conformation, gives rise to signals that are similar to
those of the agonists. As a consequence, it was pos-
sible to assume that naturally occurring mutations
caused various diseases, including some proliferative
disorders (Spiegel 1998). These observations also led
to the discovery of inverse agonism, which is an
opposing phenomenon of the constitutive activity,
presumably induced by binding and stabilizing the recep-
tor in the inactive state (Lefkowitz 1993). For this reason,
inverse agonists are also useful and effective therapeutic
tools.Another important and still unsolved challenge for
researchers is the receptor characterization of unknown
ligands or functions named ‘orphan receptors’, obtained
with the cloning techniques, whose deorphanization can
lead to the discovery of novel physiological responses.
The first example of deorphanization was the 5-HT1A
receptor encoded by the clone ‘G21’, isolated from a
size-selected human genomic DNA library (Fargin et al.
1988). To date, in spite of the many studies by groups all
over the world, only 4% of the proposed pharmacologic-
ally relevant 7TMRs are known. Some of the strategies
devised to identify the natural ligands of orphan GPCRs
were one topic of discussion at the 2007 symposium
sessions.
At the end of the 1990s, researchers had defined the
universal mechanism that regulates receptor function,
which is a sequence of stimulus-dependent receptor
phosphorylation by the kinase enzymes (GRKs) followed
by arrestin binding (Pitcher et al. 1998; Kohout and
Lefkowitz 2003). Thus, Triggle remarked in his opening
lecture of the 1999 Symposium “By the beginning of the
20th Century the foundation had been laid for a definition
of receptors that embodied the concepts of specificity,
including stereoselectivity, dose–response relationships and
transduction-concepts still in use today” (Triggle 2000). At
the beginning of the third millennium, it is possible to
synthesize receptors, define their character and properties,
and produce genetically modified animals that display our
own human receptors. The time is now ripe for advancing
our knowledge of those complex mechanisms, which have
so fascinated researchers through the years that, in his
‘Historical Review’ in 2004, Lefkowitz dedicated to them
“entirely his research career” (Lefkowitz 2004). Receptors
can have many faces and acts, as monomeric proteins, as
dimers (especially heterodimers), or as oligomers (multi-
meric quaternary structures). For example, Roberto
Maggio’s lecture at the Third Millennium Symposium
demonstrated that, when co-expressed in the same cells,
the M2 and M3 muscarinic receptor subtypes can cross-
interact with each other forming a chimeric muscarinic
M2-trunc/M3-tail receptor with new pharmacological
properties (Chiacchio et al. 2000). Consequently we could
improve or change our strategies for drug design and
development and drug-receptor interaction. The advent of
genomics provided new genetically defined targets, which
could be associated with disease states, providing new
research tools with which to define and validate targets
such as knockout mice, siRNA, and so on. The 2003
Symposium, ‘Ongoing Progress in Receptor Chemistry’,
highlighted new tools for medicinal chemists. These in-
cluded combinatorial chemistry, extremely useful in both
generating ‘hits’ and exploiting molecular space around a
‘lead’ structure, template-guided synthesis or ‘click che-
mistry’. Moreover, in the 2003 symposium, computational
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tification of their ligands are introduced, such as bi-
dimensional (2D) and three-dimensional quantitative
structure-activity relationships (QSAR), pharmacophore
searches, and virtual screening (Triggle 2004).
There was increasing therapeutic interest in molecules
which could bind one or more allosteric sites and
positively or negatively modulate (PAMs or NAMs) the
endogenous ligand response, or which themselves had an
agonist or antagonist activity (ago- or antago-allosteric
modulators) (Keov et al. 2011). This approach can
improve the ligand’s subtype selectivity, due to the higher
diversity of the allosteric domain relative to the orthosteric
one (Christopoulos 2002). Moreover, the allosteric
modulators impose a ‘ceiling’ on the magnitude of their
effect (May et al. 2007). These studies led researchers to
coin the term ‘cooperativity’ (postive or negative) to indi-
cate the action of molecules which, by interacting with
orthosteric or allosteric sites of one of the two receptors
that are part of the homo- or heterodimer, alter the same
sites’ binding propensity of the other protomer (Milligan
and Smith 2007). The introduction of allosteric modula-
tors to the system demands further revision and expan-
sion of the ternary complex model, explaining the drug
behavior, that was presented by Nobel price Whyte Black
in his opening lecture “The pharmacology of receptors at
the physiological level” of 1991 symposium. Specifically,
the model evolved to the 16-point quaternary complex
model. This model takes into account the concomitant
binding of orthosteric and allosteric ligands and G protein
on the receptor, which can exist in active and inactive
conformational states (Christopoulos and Kenakin 2002;
Bridges and Lindsley 2008). The selectivity can be engen-
dered by combining both ortho- and allosteric pharmaco-
phores within the same molecule to yield a novel class of
‘bitopic’ or ‘dualsteric’ GPCR ligands. This multitarget
approach, which somewhat overthrows the one-molecule-
one-target paradigm, has been widely applied in the treat-
ment of neurodegenerative and tumor diseases, where a
variety of pathological disorders is indicated. Due to the
novelty and potential of this therapeutic strategy, an entire
session was devoted to the topic at the 2010 Symposium
‘Trekking Through Receptor Chemistry’. At the 2010
Symposium, the utility of functional simple domain
antibodies (nanobodies) as novel GPCR modulators was
illustrated.
Throughout the years, the symposia saw an increasing
emphasis on computational techniques. In particular, as
we discussed, talks on computer-aided drug discovery
became a central part of the Camerino meetings since
the early 2000s and underwent a rapid expansion hand
in hand with the flourishing of GPCR structural studies.
The solution of the crystal structure of rhodopsin in
2000 provided for the first time a reference three-dimensional model (template) for the whole family A of
GPCRs (Palczewski et al. 2000). For the following seven
years, rhodopsin remained the only available receptor
solved crystallographically. However, starting in 2007,
the field of GPCR structural studies experienced a
dramatic expansion. At the moment twenty-one are the
GPCRs for which medium to high resolution crystal
structures have been solved, in most cases solved in
complex with multiple small molecule ligands (agonists
or antagonists) (Congreve et al. 2011). Among the
various structures of GPCRs that were recently solved
crystallographically are those of the M2 (Haga et al. 2012)
and M3 muscarinic receptors (Kruse et al. 2012), which
have been for many years one of the main foci of our
research and the symposium.
Conclusion
Let this issue’s authors describe the latest developments
for the pleasure of the readers since we were lucky
enough to hear them personally at our last Symposium
during the “G Protein-Coupled Receptors: Finally a Reality”
session. As a closing comment, we would quote an evoca-
tive line from David Triggle (Triggle 2000): “Langley and
Ehrlich might today be strangers in a strange land were
they to return, but they would surely recognize the magnifi-
cent fruits of their toil in the vineyards”.
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